In the primary analysis of OAK, a study of atezolizumab versus docetaxel in second- and third-line NSCLC, OS was improved with atezolizumab (HR, 0.73; 95% CI, 0.62-0.87); however, there was a similar PFS between the 2 arms (HR, 0.95; 95% CI, 0.82-1.10). Findings from this subanalysis of the OAK trial showed that atezolizumab had a clinical benefit in patients who received the PD-L1 inhibitor beyond progression.
exon 14 mutation–positive advanced NSCLC.”
HEMATOLOGIC MALIGNANCIES, SUPPORTIVE CARE
Michael A. Thompson, MD, PhD, medical director for the Early Phase Cancer Research Program, Patient-Centered Research at the Aurora Research Institute
Michael A. Thompson, MD, PhD
“This is somewhat of a departure from a plenary session drug study. It is of interest to patients, pharma [pharmaceutical companies], and the FDA. I previously chaired a session at the [2015 ASCO Annual Meeting] where Laura Strong, PhD, discussed this—‘The Past, Present, and Future of Patient-Reported Outcomes (PRO) in Oncology.’ PRO can be used in the short term for toxicity as well as for long-term events.”Routine molecular screening of advanced refractory cancer patients: an analysis of the first 2490 patients of the PROFILER Study (LBA100)
PROFILER is a nonrandomized, multicenter, cohort study that aims to implement a personalized cancer medicine approach by proposing to establish the genetic and immunologic profile of patients’ malignant tumors, in order to define a map of genetic and immunologic profiles for all studied types of cancer (NCT01774409). It calls for a different therapeutic management of patients, including targeted agents or immunotherapy, based on recommendations of a multidisciplinary molecular tumor board.
“This large precision medicine study from France should be of interest due to the large numbers of patients with advanced refractory cancer. This and the follow up SHIVA OS analyses (abstract 11515) will not resolve all issues in precision medicine, but may be informative about patient selection.”Next-generation sequencing in community oncology practice: beneficial or economical burden? (Abstract 102)
Researchers sought to examine the benefits and economical burden of using next-generation sequencing, especially in a nonacademic setting outside of a clinical trial, in this retrospective chart analysis of patients treated at a large community practice who had next-generation sequencing in 2015 and 2016.
... to read the full story